Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Common Equity (2017 - 2025)

Historic Common Equity for Puma Biotechnology (PBYI) over the last 9 years, with Q3 2025 value amounting to $115.3 million.

  • Puma Biotechnology's Common Equity rose 6214.83% to $115.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $115.3 million, marking a year-over-year increase of 6214.83%. This contributed to the annual value of $92.1 million for FY2024, which is 7238.31% up from last year.
  • As of Q3 2025, Puma Biotechnology's Common Equity stood at $115.3 million, which was up 6214.83% from $104.7 million recorded in Q2 2025.
  • Puma Biotechnology's Common Equity's 5-year high stood at $115.3 million during Q3 2025, with a 5-year trough of -$10.9 million in Q3 2021.
  • For the 5-year period, Puma Biotechnology's Common Equity averaged around $43.8 million, with its median value being $30.4 million (2023).
  • As far as peak fluctuations go, Puma Biotechnology's Common Equity tumbled by 231103.75% in 2021, and later surged by 98340.15% in 2022.
  • Puma Biotechnology's Common Equity (Quarter) stood at -$2.4 million in 2021, then soared by 983.4% to $21.6 million in 2022, then soared by 147.33% to $53.4 million in 2023, then skyrocketed by 72.38% to $92.1 million in 2024, then grew by 25.12% to $115.3 million in 2025.
  • Its Common Equity stands at $115.3 million for Q3 2025, versus $104.7 million for Q2 2025 and $97.1 million for Q1 2025.